Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GARDASIL immunogenicity and safety study in Chinese females and males
2014-004581-16Phase 3
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human papillomavirus infection, Cervical Cancer (CC), vulvar intraepithelial neoplasia (VIN) and 2 more comparing GARDASIL with Placebo (2 arms). Primary endpoints: Geometric mean titers for HPV types 6, 11, 16, and 18 at 1 month postdose 3, Serious adverse experiences and 2 more.
02
Drugs
qHPV vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)vulvar intraepithelial neoplasia (VIN)vaginal intraepithelial neoplasia (VAIN)anogenital warts
Beyond the preview
Go deeper on 2014-004581-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004581-16.